Comparing Novel and Emerging Treatments With Traditional Pharmacology for Schizophrenia: A Clinical Review

Authors

• Lydia Ramos, University of LynchburgFollow

Specialty

Psychiatry

Advisor

Professor Thomas Colletti

Abstract

This paper provides an overview of the current pharmacological landscape for Schizophrenia treatment. Schizophrenia is a globally prevalent condition (0.3%) associated with significant disability and a 10–25 year reduction in life expectancy. While pharmacological management has historically relied on dopaminergic pathways, the recent approval of Cobenfy—a novel muscarinic agonist—marks the first pioneering mechanism of action in seventy years. This review searched PubMed and Google Scholar and synthesized data from seven high-quality sources, including network meta-analyses and systematic reviews, to evaluate the current treatments for Schizophrenia. Keywords used for the search included “Schizophrenia”, “treatment”, and many variations of how antipsychotics are named in the literature.  Findings highlight significant heterogeneity in patient response regarding both efficacy and tolerability. Notably, long-acting injectable (LAI) formulations demonstrated superior efficacy over oral monotherapies. LAI formulations do not present with fewer adverse effects than their oral counterparts, except for less hyperprolactinemia in Risperidone LAI formulations. Though Clozapine has been the gold standard for treatment-resistant Schizophrenia for years, there is a subpopulation of individuals who demonstrate ultra-treatment-resistance. By bypassing traditional dopaminergic pathways, muscarinic agents like Cobenfy offer a promising alternative that avoids common movement disorders and metabolic dysfunction. These findings underscore a shift toward precision psychiatry and genetic integration. Future research should prioritize head-to-head antipsychotic comparisons, longitudinal designs, and targeted studies on ultra-treatment-resistant subpopulations.

Recommended Citation

Ramos L. Comparing Novel and Emerging Treatments With Traditional Pharmacology for Schizophrenia: A Clinical Review. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2026; 8(1).